Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

September 30, 2014

Study Completion Date

October 31, 2014

Conditions
Lung Cancer
Interventions
DRUG

erlotinib hydrochloride

given orally

DRUG

gemcitabine hydrochloride

given IV

Trial Locations (11)

27607

Rex Cancer Center at Rex Hospital, Raleigh

28025

Batte Cancer Center at Northeast Medical Center, Concord

31405

Summit Cancer Care, Savannah

37660

Kingsport Hematology-Oncology Associates, Kingsport

38104

University of Tennessee Cancer Institute - Memphis, Memphis

72703

Highlands Oncology Group - Fayetteville, Fayetteville

60201-1781

Evanston Hospital, Evanston

07601

Hackensack University Medical Center Cancer Center, Hackensack

27599-7295

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill

28232-2861

Blumenthal Cancer Center at Carolinas Medical Center, Charlotte

28302-2000

Cape Fear Valley Medical Center Cancer Center, Fayetteville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT00283244 - Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC | Biotech Hunter | Biotech Hunter